PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PharmAla Biotech Holdings Inc. has partnered with the University of Texas, San Antonio, to supply a unique dosage form of their proprietary LaNeo™ MDMA for a clinical trial. Additionally, the company has announced the publication of a patent application for APA-01, a new molecular entity, signaling growth in their intellectual property portfolio.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.